Taeniasis, a zoonotic illness transmitted between animals and humans, is a focal point of our company's commitment to pioneering advancements in disease control. Our dedicated research and development services in taeniasis are designed to push the boundaries of scientific innovation. With our integrated approach, we strive to offer pharmaceutical companies worldwide expert solutions.
Overview of Taeniasis
Taeniasis, a parasitic infection caused by tapeworms from the Taenia genus, notably Taenia saginata (beef tapeworm) and Taenia solium (pork tapeworm), is typically contracted through the consumption of undercooked or contaminated meat containing the larval cysticerci of these parasites. In the case of T. solium, individuals can also acquire the infection through fecal-oral transmission by ingesting eggs, potentially leading to a more severe condition called neurocysticercosis when larvae infiltrate the central nervous system.
Fig.1 Taenia spp. egg found in human feces. (Symeonidou, I., et al., 2018)
Vaccine Development for Taeniasis
Porcine Vaccines
Significant strides have been made in the development of vaccines against porcine cysticercosis, a disease closely related to taeniasis. Two leading vaccine candidates, SP3VAC and TSOL18, have shown high efficacy in protecting pigs from experimental and natural challenges of Taenia solium infection.
Bovine Vaccines
Vaccination against Taenia saginata in cattle has also been explored. The vaccine TSA9/TSA18 has shown high efficacy in protecting cattle from Taenia saginata cysticercosis. However, commercialization of this vaccine is not currently being pursued due to a lack of commercial viability.
Therapeutics Development for Taeniasis
The cornerstone of taeniasis therapeutic revolves around anthelmintic drugs, which are effective against the adult stages of Taenia species. Some of the most commonly used drugs include:
- Praziquantel: This drug has demonstrated high efficacy (95%) in treating taeniasis and is considered a first-line therapeutic.
- Niclosamide: With an efficacy of 85%, niclosamide is another effective therapeutic for taeniasis.
- Albendazole: This drug has shown the ability to cure 100% of Taenia spp. cases when administered in a triple-dose regimen.
Our Services
We offer comprehensive services in vaccine development, covering the entire process from antigen identification to conducting preclinical trials. Our adept team leverages advanced technologies to create vaccines that prioritize both effectiveness and safety.
Additionally, our therapeutic development services revolve around the research, synthesis, and evaluation of innovative anthelmintic drugs. Our focus lies in enhancing the efficacy of current medications, minimizing side effects, and exploring potential new drug options.
Disease Models
- Taenia solium Infection Pig Models
- Taenia saginata Infection Cattle Models
- Taenia asiatica Infection Gerbils Models
Other species: Mice, Rats, Voles, Hamsters, Dogs, or Monkeys
The development of vaccines and therapeutics for taeniasis is a complex process that requires a deep understanding of the disease, its causative agents, and the host-parasite interactions. Our company is committed to advancing the science of taeniasis control through innovative research and development services. If you are interested in our services, please feel free to contact us.
References
- Okello, Anna L., and Lian Francesca Thomas. "Human taeniasis: current insights into prevention and management strategies in endemic countries." Risk Management and Healthcare Policy (2017): 107-116.
- Symeonidou, Isaia, et al. "Human taeniasis/cysticercosis: a potentially emerging parasitic disease in Europe." Annals of gastroenterology 31.4 (2018): 406.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
